CT Colonography Cost-Effective, Clinically Effective for CRC Screening
By Elana Gotkine HealthDay Reporter
MONDAY, June 16, 2025 -- Computed tomography colonography (CTC) is cost-effective and clinically effective for colorectal cancer (CRC) screening, according to a study published online June 10 in Radiology.
Perry J. Pickhardt, M.D., from the University of Wisconsin School of Medicine & Public Health in Madison, and colleagues compared the clinical efficacy and cost-effectiveness of CRC screening with CTC versus multitarget stool DNA (mt-sDNA) testing. Using updated natural history evidence for colorectal polyps applied to a hypothetical 10,000-person cohort representative of the 45-year-old U.S. population, a Markov model was constructed. Three screening strategies were modeled with these data: mt-sDNA testing every three years, conventional CTC (CTCconv), and surveillance CTC (CTCsurv) strategies. The CTCconv strategy involved immediate polypectomy for all polyps measuring at least 6 mm every five years, whereas the CTCsurv strategy involved three-year CTC follow-up for small polyps measuring 6 to 9 mm and polypectomy for polyps ≥10 mm.
The researchers found that the cumulative incidence of CRC was 7.5 percent without screening, which was reduced by 59, 75, and 70 percent with mt-sDNA, CTCconv, and CTCsurv, respectively. The estimated programmatic costs were $4,955, $6,011, $4,422, and $3,913 for no screening, mt-sDNA, CTCconv, and CTCsurv, respectively. Per quality-adjusted life-year (QALY) gained, the estimated cost was $8,878 for mt-sDNA, while both CTC strategies were cost-saving; consequently, CTC strategies dominated over mt-sDNA and no screening. The CTCconv strategy was less cost-effective than the CTCsurv strategy, with costs associated with more optical colonoscopies not offsetting the small gains in QALYs. When CRC screening began at ages 50 and 65 years, the results were similar.
"Among the safe, minimally invasive colorectal cancer screening options, CT colonography is more effective at preventing and detecting cancer -- and is also more cost-effective -- than stool DNA testing," Pickhardt said in a statement.
Several authors disclosed ties to the biotechnology and medical technology industries, including Bracco Diagnostics, which partially funded the study.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
2,770 Cases of Arboviral Disease Reported in 48 States and D.C. in 2023
TUESDAY, June 17, 2025 -- In 2023, 48 states and the District of Columbia reported 2,770 human arboviral disease cases, with West Nile Virus (WNV) being the most common, according...
New Model Developed for Identifying DVT in Epithelial Ovarian Cancer
TUESDAY, June 17, 2025 -- A model with eight independent risk factors can predict the risk for deep vein thrombosis (DVT) in patients with epithelial ovarian cancer (EOC)...
Electronic Nudge Letters Do Not Improve Guideline-Directed Medical Therapy in CKD
TUESDAY, June 17, 2025 -- Neither delivery of electronic nudge letters nor letters to general practice increase uptake of guideline-directed medical therapy (GDMT) among patients...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.